Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease

International Clinical Psychopharmacology

Volumn 28, Issue 4, 2013, Pages 214-216

  Edlinger, Monika ^a   Seppi, Klaus ^a   Fleischhacker, Wolfgang ^a   Hofer, Alex ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

aggressive behavior; combined psychopharmacological treatment; psychiatric symptoms in HD; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; FLUPENTIXOL DECANOATE; OLANZAPINE; REBOXETINE; RISPERIDONE; TETRABENAZINE;

ADULT; AGGRESSION; ANHEDONIA; ARTICLE; BRADYKINESIA; CASE REPORT; CLINICAL FEATURE; CONFUSION; DAILY LIFE ACTIVITY; DELUSION; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DYSARTHRIA; GRANDIOSE DELUSION; HEAD INJURY; HOSPITAL DISCHARGE; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; ICD-10; IRRITABILITY; LISTLESSNESS; MALE; MOTIVATION; MUTISM; PARANOIA; PARANOID SCHIZOPHRENIA; PERSONAL HYGIENE; PRIORITY JOURNAL; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT; THINKING IMPAIRMENT;

ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; HUNTINGTON DISEASE; MALE; MORPHOLINES; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; TREATMENT OUTCOME;

EID: 84879893064     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328361e145     Document Type: Article

References (22)

1. Amann B, Sterr A, Thoma H, Messer T, Kapfhammer HP, Grunze H (2000). Psychological changes preceding motor symptoms in Huntington's disease: a report of four cases. World J Biol Psychiatry 1:55-58.
2. Armstrong MJ, Miyasaki J (2012). Evidence-based Guideline: Pharmacologic treatment of chorea in Huntington's disease report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 79:597-603.
3. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A (1994). Clozapine in Huntington's chorea. Neurology 44:821-823. (Pubitemid 24158793)
4. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB (2009). Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 24:126-129.
5. Bürger K, Mergner R, Arbusow V, Padberg F, Hampel H (2002). Late onset Huntington's disease-a differential diagnosis of Alzheimer's disease. Nervenarzt 73:870-873. (Pubitemid 36062324)
6. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979). The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317-320. (Pubitemid 9153307)
7. Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, et al. (2009). Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 5:1-4.
8. Cummings JL (1995). Behavioral and psychiatric symptoms associated with Huntington's disease. Adv Neurol 65:179-186.
9. Dubini A, Bosc M, Polin V (1997). Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 7: 49-55, discussion 71-73.
10. Fleischhacker WW (1999). Clozapine: a comparison with other novel antipsychotics. J Clin Psychiatry 60:30-34. (Pubitemid 29283180)
11. Frogley C, Taylor D, Dickens G, Picchioni M (2012). A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 20:1-21.
12. LinWC, Chou YH (2008). Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 165:1207-1208.
13. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009). Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 8:CD006456.
14. Mestre TA, Ferreira JJ (2012). An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Disord 18:316-320.
15. Oulis P, Mourikis I, Konstantakopoulos G, Papageorgiou SG, Kouzoupis AV (2010). Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease. J Neuropsychiatry Clin Neurosci 22:352ce4-352ce5.
16. Raedler TJ, Jahn H, Arlt J, Kiefer F, Schick M, Naber D, et al. (2004). Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 19:366-369. (Pubitemid 39207964)
17. Rittmannsberger H, Gebetsberger B, Pichler R, Rotaru J, Trattmayr N, Zaunmü ller T. (2011). A case of affective disorder with psychotic symptoms as late manifestation of Huntington's chorea. Psychiatr Prax 38:306-308.
18. Rosenblatt A (2007). Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci 9:191-197. (Pubitemid 47075466)
19. Rosenblatt A, Leroi I (2000). Neuropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics 41:24-30. (Pubitemid 30062894)
20. Sackley C, Hoppitt TJ, Calvert M, Gill P, Eaton B, Yao G, et al. (2012). Huntington's disease: current epidemiology and pharmacological management in UK primary care. Neuroepidemiology 37:216-221.
21. Suchowersky O (2013). Huntington disease: management. Available at: http://www.uptodate.com/contents/huntington-disease-management#H24. [Accessed 15 March 2013].
22. Van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA (1997). Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 63:35-39. (Pubitemid 27317358)